Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata

July 2025 in “ Journal of Cosmetic Dermatology ”

Lynne Yao, Rongqiao He, N C Lan, Yongmei Lv

Tofacitinib Janus kinase inhibitor JAK inhibitor alopecia areata corticosteroid therapy Ritlecitinib JAK–STAT signaling pathway

From the encyclopedia

Tofacitinib →

a JAK inhibitor for alopecia areata and other autoimmune conditions

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Studysummary In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

Alopecia areata (AA) is an autoimmune disorder that can be treated with JAK inhibitors like tofacitinib, but relapse is common, affecting 58% of patients. A case study of a 26-year-old female with alopecia universalis showed initial improvement with tofacitinib, but hair loss resumed, leading to a switch to ritlecitinib. The study suggests that personalized treatment strategies and combination therapies are necessary to maintain remission. JAK inhibitors work by suppressing immune attacks and promoting hair follicle stem cell proliferation. Monitoring biomarkers related to immune response and hair follicle signaling pathways can help evaluate treatment efficacy. Strategies to manage relapse include combined drug therapy, increasing the tofacitinib dose, or switching to other JAK inhibitors, while considering the risks of serious side effects.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

21 / 21 results

research Safety and Efficacy of Tofacitinib in 97 Alopecia Areata Patients

May 2024 in “Journal of cosmetic dermatology”

In this retrospective study, oral tofacitinib treatment for at least 6 months improved scalp hair loss in 69.1% of alopecia areata patients, with patchy AA cases responding better compared to other subtypes, and no significant adverse effects were reported.

Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-Centre Real-World Retrospective Study

research Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-Centre Real-World Retrospective Study

December 2023 in “Acta dermato-venereologica”

This retrospective cohort study reported that oral tofacitinib was effective in treating alopecia areata, with 83.2% of patients showing improvement and 16.0% achieving complete remission. Earlier intervention and previous hair regrowth were linked to better outcomes, and no severe adverse events were observed.

research Alopecia Areata: Current Treatments and New Directions

57 citations , August 2023 in “American Journal of Clinical Dermatology”

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

research Switching Between Tofacitinib and Baricitinib in Alopecia Areata: A Review of Clinical Response

April 2023 in “Journal of the American Academy of Dermatology”

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study

research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study

8 citations , June 2022 in “Frontiers in Medicine”

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers

36 citations , December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

research Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management

290 citations , August 2021 in “Clinical Reviews in Allergy & Immunology”

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

research Resident Memory T Cells in Autoimmune Skin Diseases

50 citations , May 2021 in “Frontiers in immunology”

This review discusses how tissue resident memory T cells contribute to autoimmune skin diseases like vitiligo and psoriasis, highlighting their role in continuous immune activation, and reports no new clinical results.

research Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata

42 citations , April 2021 in “JCI insight”

In this study, selective inhibition of JAK3 signaling effectively prevented and reversed alopecia areata in a mouse model, while JAK2 inhibitors did not restore hair growth.

research Alopecia Areata Flare Patterns in Children and Young Adults on Systemic Tofacitinib

7 citations , March 2021 in “Journal of the American Academy of Dermatology”

This study observed that some children and young adults with alopecia areata experienced flares during long-term tofacitinib treatment, despite initial successful hair regrowth.

research The Effect of JAK Inhibitor on Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells

16 citations , July 2020 in “International Journal of Molecular Sciences”

This study found that ruxolitinib modulated inflammatory changes and stimulated growth factor signals by blocking the JAK-STAT pathway in an in vitro model of alopecia areata.

research Benefit and Risk Profile of Tofacitinib for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis

54 citations , September 2019 in “Journal of the European Academy of Dermatology and Venereology”

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

research Combination Tofacitinib and Oral Minoxidil Treatment for Severe Alopecia Areata

23 citations , September 2019 in “Journal of The American Academy of Dermatology”

In this retrospective analysis, combination therapy with tofacitinib and oral minoxidil led to significant scalp hair regrowth in patients with severe alopecia areata, with 67% achieving at least 75% regrowth, although the small sample size limits the findings.

research Minoxidil And Its Use In Hair Disorders: A Review

117 citations , August 2019 in “Drug Design Development and Therapy”

This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.

research Alteration of Serum and Tissue Tumor Necrosis Factor Alpha Levels: A Possible Mechanism of Action of Oral Pulse Steroids in the Treatment of Alopecia Areata

5 citations , October 2018 in “Journal of Cosmetic Dermatology”

This study found that oral pulse steroids significantly reduced serum and tissue levels of TNF-α in patients with alopecia areata, correlating with clinical improvement.

research Efficacy of Topical Tofacitinib in Promoting Hair Growth in Non-Scarring Alopecia: Possible Mechanism via VEGF Induction

27 citations , September 2017 in “Archives of Dermatological Research”

In this study, topical tofacitinib significantly increased hair regrowth in mice compared to minoxidil or vehicle, potentially due to elevated VEGF levels and reduced inflammation.

Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

research Minoxidil Activates β-Catenin Pathway in Human Dermal Papilla Cells: A Possible Explanation for Its Anagen Prolongation Effect

88 citations , February 2011 in “Journal of Dermatological Science”

This study found that topical minoxidil modestly extended the anagen phase in mice by activating β-catenin activity in dermal papilla cells.